{"id":1023015,"date":"2026-11-20T16:04:32","date_gmt":"2026-11-20T21:04:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/"},"modified":"2026-11-20T16:04:32","modified_gmt":"2026-11-20T21:04:32","slug":"kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/","title":{"rendered":"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026<\/em>\n      <\/p>\n<p>WATERTOWN, Mass., Nov.  20, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Orh9ySq2CB4Axck6CFGW_htduWyf_2zAhG5zols6c2CDhmFxPOKpXj_NTi8SBEpRcFOWMpBMVy0EYxeL2O-pg__GDgLc9eMPqAJEV6o-HaY=\" rel=\"nofollow\" target=\"_blank\">Kymera Therapeutics, Inc.<\/a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.<\/p>\n<p>To join the video call or view the livestreamed webcast, please register via this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=we15jYlhZWhszlReuczKPNJHpxdOdEAhmZZZC06_d5POJJVvrGKrVD3IwyJHwPMko7Thyj2qkdoVQcCPp2ywqvCqT4vtPNQIAvv0cNAoHUPoISSXvwKbg3gAVJT05yRj\" rel=\"nofollow\" target=\"_blank\"><strong>link<\/strong><\/a><strong>,<\/strong> or visit \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VfkpxX9rNGS31sEFF-ZlpO0ZN9lEk2UN2mYPUQAXv0IF_Lz5OLQLpWMW5hee3XcG2kT67uyX65LGpH_RdWTqJkpPqba3Pu92PqFIpwEFnTeUHyzN-3QVWQI08xLFF1D5\" rel=\"nofollow\" target=\"_blank\">News and Events<\/a>\u201d in the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EwpVxm7Gekn0qIVZly_d7xUvDA_dGtnX9KtMzVE2I6DAQUwXN4L9nOlW3vVgYi_R6Sz07bQA2Wq2MJw1BIXedVRlApTa3pL3hs7cJoi2VUg=\" rel=\"nofollow\" target=\"_blank\">www.kymeratx.com<\/a>. A replay of the webcast and copy of the presentation will be available following the event.\u00a0<\/p>\n<p>\n        <strong>About KT-621 <\/strong><br \/>\n        <br \/>KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4\/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in clinical development in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6jiO1C-5GyUZrjuIcEPzq2hPmDEmd3oPPz_f-aRI6RKX4BqvWMQxS_uinZfgtZhIi1ShY2EF20tV2NtfMwq0lxi83bsWye66ld1p9rfpfFw=\" rel=\"nofollow\" target=\"_blank\">AD and asthma<\/a>. KT-621 has the potential to transform treatment paradigms by offering a safe, effective, oral option for millions of patients worldwide living with Type 2 diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.<\/p>\n<p>\n        <strong>About Kymera Therapeutics<\/strong>\u00a0<br \/>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients\u2019 lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston\u2019s top workplaces for the past several years. For more information about our science, pipeline and people, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EwpVxm7Gekn0qIVZly_d73BScRtCJEHcc1Ewpxks88HNvKRD3nRrv6BHo8gnBXqWknXH2S3wQogdUuFj57Nsh4jGZ1QKpc7Vzq02PmmwutA=\" rel=\"nofollow\" target=\"_blank\">www.kymeratx.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b8WSAWbV8xD6bJu-85fcSQ1i0GaPdkh8yoKEacKjEQhi_x2dasxYnXkuYvhd8hqQirqc2aNGSyU9HpebJ5WqgA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7qcSPonzhBT4inUmyJj1d_ZX-18uJGKJU0jYv1OW4yvOFrnDYy-_dbUWeeZgbkSINSTERkPHXrA1MMGqTOqMG-1u44sfzbe5usm58wWrJ_Rsw2NCjIXJF5j5-uJecqb6\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Justine Koenigsberg<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3kwPTKxJZH6lMon64MiOymGHV4eX-n9eXX7atg-uyBT6LBXtceveHCr4314TGVSXt2s8Qu3zsq9aBoKkd2h6_cPXn-N82w1Kb8sfrxi23bE=\" rel=\"nofollow\" target=\"_blank\">investors@kymeratx.com<\/a><br \/>857-285-5300\u00a0<\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <br \/>Matthew Henson <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W6j-MZr0Ws53jdvlqXvOUPTZbmruQF2d-Ue_lrZd-QcKhqKVXSP2eCjpn67trH8Owiw_S1OdYmw08e2OSEXn71UDl6HpxkVhhSunEZxT8G4=\" rel=\"nofollow\" target=\"_blank\">media@kymeratx.com<\/a><br \/>857-285-5300<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzEyZjFiYzctNDEzNS00NWMxLWJkZmQtMTYxN2Q1NjhkYTI0LTEyMTIzODUtMjAyNi0xMS0yMC1lbg==\/tiny\/Kymera-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026 WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. To join the video call or view the livestreamed webcast, please register via this link, or visit \u201cNews &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1023015","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026 WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. To join the video call or view the livestreamed webcast, please register via this link, or visit \u201cNews &hellip; Continue reading &quot;Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-20T21:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026\",\"datePublished\":\"2026-11-20T21:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/\"},\"wordCount\":397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/\",\"name\":\"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=\",\"datePublished\":\"2026-11-20T21:04:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 - Market Newsdesk","og_description":"Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026 WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. To join the video call or view the livestreamed webcast, please register via this link, or visit \u201cNews &hellip; Continue reading \"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-20T21:04:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026","datePublished":"2026-11-20T21:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/"},"wordCount":397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/","name":"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=","datePublished":"2026-11-20T21:04:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTgyMSM3OTc3NjAwIzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-announce-kt-621-broaden2-phase-2b-atopic-dermatitis-trial-results-on-november-23-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1023015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1023015"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1023015\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1023015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1023015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1023015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}